News | May 13, 2025
Morepen Board proposed dividend after 23 years
Scores highest PAT of Rs. 118 crore in FY25
Scores highest PAT of Rs. 118 crore in FY25
The National IP Awards recognize outstanding contributions to India’s innovation economy through effective IP creation and commercialization
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America
Mehta is an industry veteran with over 25 years of experience in the pharmaceutical industry
Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
Q3 FY25 revenue up 24% to Rs 3,230 crore
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Subscribe To Our Newsletter & Stay Updated
